Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
The raw material is obtained from epichlorohydrin, trimethylamine and acetic acid in a chemical-synthetic process
GIP Agonism Effect in Diabetic Nephropathy The nephroprotective effect of tirzepatide has not been directly studied, however, the effect of GIP agonism on inflammation has been extensively documented (Figure 2)
The disconnect stems from how GLP-1 medications are traditionally prescribed and supported
10.1002/osp4.84 37
